about
Genetically distinct subsets within ANCA-associated vasculitisRisk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathyBarriers to successful implementation of care in home haemodialysis (BASIC-HHD):1. Study design, methods and rationale.Plasma transforming growth factor beta(1) and platelet activation: implications for studies in transplant recipients.Plasma TGF beta in systemic sclerosis: a cross-sectional study.Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathyDevelopment of novel single-stranded nucleic acid aptamers against the pro-angiogenic and metastatic enzyme heparanase (HPSE1)rhErythropoietin-b as a tissue protective agent in kidney transplantation: a pilot randomized controlled trial.Genetic Polymorphisms and Peritoneal Membrane Function.Self-cannulation for haemodialysis: patient attributes, clinical correlates and self-cannulation predilection modelsHealthcare decision-making in end stage renal disease-patient preferences and clinical correlates.A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure.Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathyGlobal analysis reveals the complexity of the human glomerular extracellular matrix.A collaborative approach to understanding EPS: the European perspective.The genetic contribution to recurrent autoimmune nephritis.Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.Frequent elevation of tissue polypeptide antigen in the sera of workers exposed to bladder carcinogens.Trophoblast-derived heparanase is not required for invasion.Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.Investigation of IgG4 levels in atopic patients using a competitive inhibition assay employing biotinylated IgG4 myeloma and avidin peroxidase.A road map for efficient and reliable human genome epidemiology.Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy.Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.A multiwell format assay for heparanase.Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes.VEGF -460 genotype plays an important role in progression to chronic kidney disease stage 5.Plasmodium falciparum malaria in south-west Nigerian children: is the polymorphism of ICAM-1 and E-selectin genes contributing to the clinical severity of malaria?Activated human neutrophils express vascular endothelial growth factor (VEGF).Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy.Development and functional capacity of transplanted rat metanephroi.Acute arteriovenous access failure: long-term outcomes of endovascular salvage and assessment of co-variates affecting patency.A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).The identification of allo- and auto-lymphocytotoxic antibodies in serum, in the presence of rabbit antithymocyte globulin.VEGF Polymorphisms Are Associated with Severity of Diabetic RetinopathyProof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosisProspective controlled pilot study of arteriovenous fistula placement using the novel Optiflow device
P50
Q28943363-730FCC83-80AD-40D5-AD8C-FE1B2635F448Q28943554-DD9B7B98-3B9E-48A8-97EB-CF8AF5682CF4Q31139590-6BAAB908-38BD-49EC-898D-5B0CFD9B4CC7Q31832612-CEC8E24A-8175-4B1D-84CE-559FD3D11239Q33566799-9A4E7CE9-17B4-450D-8AEF-11AB22E68D34Q34008949-6D7571AF-56FA-4137-85D0-2F6B1E6ACE3BQ34311783-2875FFC8-C624-4B1B-BA0C-92E3AD453E8BQ35089582-41C58C11-6D91-4124-8135-C2C9ACB6DB91Q35419909-3B79819F-C9B6-4FFF-8E54-A13CB9C5ABD7Q35625110-826BFCF1-FDEE-4F4E-8CD9-10E51454ED37Q35842605-4AB0B683-A45E-46CB-B6B0-9CA9E1E9EA73Q36081460-C90486BF-8F98-4EB3-8B0B-BF16BA01E5B6Q36284624-F28B9DCB-788B-49EC-B091-BDD92F4F784CQ36719250-5001ECAB-4B67-4586-AD22-383A9AC72D22Q37733558-F71D663F-8B37-44CC-A1EC-775F94248C1FQ37873656-99B3C431-FE0B-492F-8478-2F5CEB1C2A41Q38196037-63570926-A733-4114-9FC4-A0B3F876CCA4Q39476063-8204EB23-D917-4E58-920D-956DF2495D7DQ39519398-B4E153A6-D174-4E59-B5E4-26F27BB015A7Q40004292-17E1445C-151B-4554-9DDF-87C4EC7307F5Q40361784-9AE53257-C229-4949-8C10-27E097EA84E3Q40531723-EDA2D764-6F1C-4FAF-8366-DC263A930ACEQ40810506-CBA5D3C2-07BD-46B6-8996-3FE6FCF5504FQ42680046-36294BD6-311F-4B7D-8E71-3A8051C4DBB9Q43123391-ACEE5491-283B-47B3-BF26-AB984691A961Q43236774-3F2C5554-B44D-4FBC-999C-750A394D828AQ44555544-69569FA7-E1E7-480B-8596-8546E8EAD946Q44779289-F9CC723A-D00D-4B52-8553-49DDF4D320B6Q46620891-1AEE7344-A0BE-4CEA-8000-8D984EC106AAQ46776463-BF05C141-73BF-4CB5-94F4-F27124B2B131Q48002394-3D290B96-1968-4058-8A07-440C46B907F1Q48727704-FDC7968E-F459-44B0-8E15-65729D6A67EAQ51038554-EB036FB8-6AF7-467E-9C78-AC6A68418607Q51732985-B81584A9-6FF5-45C4-86F5-98ABEFBC32D6Q53293569-DCDD55FD-39F8-49D7-A15B-1EDD37DEE1BAQ53462757-0311E8EA-FD54-4124-ABFE-6EDA8ADF6409Q54392118-301D0DDE-1462-4C28-8051-ED6B3100A0EFQ57010448-BC492220-1C44-414C-89B7-B039E681A821Q57797449-92D00E2D-5AC5-40B1-8186-6B023EE4FE36Q59292832-736ADA22-CB3C-4B66-8601-31E1858BF0BA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paul E Brenchley
@ast
Paul E Brenchley
@en
Paul E Brenchley
@es
Paul E Brenchley
@nl
Paul E Brenchley
@sl
type
label
Paul E Brenchley
@ast
Paul E Brenchley
@en
Paul E Brenchley
@es
Paul E Brenchley
@nl
Paul E Brenchley
@sl
prefLabel
Paul E Brenchley
@ast
Paul E Brenchley
@en
Paul E Brenchley
@es
Paul E Brenchley
@nl
Paul E Brenchley
@sl
P106
P21
P31
P496
0000-0003-1290-9919